cartitude-4: cilta-cel vs standard of care pvd or dpd in lenalidomide-refractory multiple myeloma
Published 1 year ago • 793 plays • Length 11:43Download video MP4
Download video MP3
Similar videos
-
8:16
results from cartitude-4: cilta-cel for lenalidomide-refractory multiple myeloma
-
1:45
cartitude-2 update: cilta-cel in relapsed and lenalidomide-refractory patients with multiple myeloma
-
4:25
updated results from cartitude-1: phase 1b/2study of cilta-cel in pts with rr multiple myeloma
-
6:57
asco23 - lba106: phase 3 results from cartitude-4: cilta-cel versus standard of care in lenalido...
-
4:10
cilta-cel versus conventional treatment in patients with relapse/refractory multiple myeloma
-
1:54
cilta-cel vs standard of care in functional high-risk myeloma: findings from cartitude-4
-
5:05
patient-reported outcomes in cartitude-4: cilta-cel vs soc in r/r multiple myeloma
-
5:42
comparison of outcomes with cilta-cel in cartitude-1 vs rw soc for pts w/ triple-class exposed rrmm
-
9:56
ide-cel vs standard regimens for high-risk multiple myeloma: karmma-3 analysis | asco 2023
-
8:45
updates on clinical data of cilta-cel in cartitude-2 cohort a among progressive mm patients
-
4:22
eha 2023 | cartitude4 clinical trial
-
9:34
neurologic adverse effects in pts with mm treated with cilta-cel in cartitude-2
-
9:03
cartitude-1: final results of ciltacabtagene autoleucel in heavily pretreated relapsed refractory mm
-
2:33
latest results from the cartitude-2 trial of cilta-cel in progressive multiple myeloma
-
1:26
cilta-cel vs. therapies from real-world clinical practice for triple-class exposed myeloma
-
5:03
cartitude-2: evaluating car t therapy cilta-cel in multiple myeloma patients who had early relapse
-
3:52
updated results (2 years post-lpi) in phase 1b/2 (cartitude-1) study of cilta-cel in rrmm patients
-
6:30
effects of refractory status to lenalidomide of xvd versus vd in pts with previously treated mm
-
3:54
cilta-cel as a potential new soc for r/r multiple myeloma: insights from the cartitude-4 trial